[Invasive rhinocerebral aspergillosis occurred during myelosuppressive phase after chemotherapy: a case report and literature review].
OBJECTIVE
To report a case of invasive rhinocerebral aspergillosis (IRA) during myelosuppressive phase after chemotherapy and the treatment outcome.


METHODS
A patient with acute non-lymphoblastic leukemia (M(2a)) occurred IRA during myelosuppressive phase after chemotherapy and was treated with amphotericin B (AmB, including AmB-L), garlicin, 5-flucytosine (5-FC), fluconazole, itraconazole, ketoconazole, econazole and griseofulvin with twice of cerebrotomy lesion resections and cerebral decompressions.


RESULTS
Though the survival time of this patient is a little longer than the others, she finally died of uncontrolled infection.


CONCLUSIONS
For most of the IRA, there remains no effective treatment. The best treatment is AmB in combination with surgical excision.
Yu
Z
Z
HSCT Center, Affiliated Hospital of Academy of Military Medical Science, Beijing 100039, China.
Chen
H
H
Jiang
M
M
Yang
S
S
Hu
L
L
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D020314:Central Nervous System Fungal Infections / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009668:Nose Diseases / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome
D000935:Antifungal Agents